Glutathione is one of five compounded formulations in the first wave of Hims & Hers' Peptides+ platform, and CNBC describes it as a peptide promoted for anti-aging and athletic recovery. It is also one of the few compounds in that launch where the published human evidence and the federal safety record can both be checked, and neither is flattering.
How it is being sold
Hims & Hers launched Peptides+ across the U.S. as a personalized program pairing compounded peptide and nutrient therapies, including glutathione, with at-home blood collection and ongoing clinical oversight. The same launch covers sermorelin, NAD+, vitamin B-12 and L-carnitine.
None of the company's specific compounded products are FDA-approved, though Hims says they are authorized by law and made by pharmacies licensed and inspected by state boards of pharmacy. The legal route opened after an October HHS policy under which the FDA said it will not take enforcement action against licensed pharmacies compounding six unapproved peptides while formal rules are reviewed.
Skin lightening
Intravenous glutathione is widely marketed for skin whitening and is not FDA-approved for that purpose, CNBC reported. A small study in the Journal of Pakistan Association of Dermatologists evaluating IV glutathione found the treatment was "not very effective" for skin-lightening, and that it lost efficacy over time.
Reported adverse events
In August the FDA said it had received reports of at least 30 patients who experienced adverse events after receiving compounded IV glutathione, alone or combined with other ingredients, from different compounding pharmacies. All of the glutathione tied to those reports came from the same wholesale distributor and was labeled dietary supplement grade, which is not an appropriate ingredient for injectable drugs, and two Texas pharmacies recalled glutathione injectables over elevated endotoxin levels.
What Isn't Established
Dosing is the clearest gap. Paul Knoepfler of UC Davis Health told CNBC that "the dosing for these products really has not been established," and that injecting too much of a synthetic peptide risks immune responses. Hims' own chief medical officer, Dr. Anant Vinjamoori, said the company does not have the data it is used to having with compounds like these.
State of the evidence
What exists for glutathione is one small negative dermatology study and a federal adverse-event file. That is a slim base for a compound now reaching a platform with millions of subscribers.
Comments (0)
Discussion happens on Reddit.
Go to r/PeptideNewsroomQuestions and corrections go to r/PeptideNewsroom.